Tolerogenic dendritic cell therapy for rheumatoid arthritis: Where are we now?

Clinical and Experimental Immunology

Volumn 172, Issue 2, 2013, Pages 148-157

  Hilkens, C M U ^a   Isaacs, J D ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Autoimmune disease; Dendritic cells; Immunotherapy; Rheumatoid arthritis; Tolerance

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 4; MICRORNA; MICRORNA 23B; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ARTICLE; AUTOIMMUNE DISEASE; CELL THERAPY; CHRONIC INFLAMMATION; DENDRITIC CELL; HUMAN; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMORY T LYMPHOCYTE; MONOCYTE; MONONUCLEAR CELL; NATURAL KILLER T CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TOLEROGENIC DENDRITIC CELL THERAPY; UPREGULATION;

ADOPTIVE TRANSFER; ARTHRITIS, RHEUMATOID; AUTOIMMUNITY; DENDRITIC CELLS; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY;

EID: 84876091796     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/cei.12038     Document Type: Article

References (102)

1. Londei M, Savill CM, Verhoef A etal. Persistence of collagen type II-specific T-cell clones in the synovial membrane of a patient with rheumatoid arthritis. Proc Natl Acad Sci USA 1989; 86:636-640.
2. Fritsch R, Eselbock D, Skriner K etal. Characterization of autoreactive T cells to the autoantigens heterogeneous nuclear ribonucleoprotein A2 (RA33) and filaggrin in patients with rheumatoid arthritis. J Immunol 2002; 169:1068-1076.
3. van Bilsen JH, van Dongen H, Lard LR etal. Functional regulatory immune responses against human cartilage glycoprotein-39 in health vs. proinflammatory responses in rheumatoid arthritis. Proc Natl Acad Sci USA 2004; 101:17180-17185.
4. de Jong H, Berlo SE, Hombrink P etal. Cartilage proteoglycan aggrecan epitopes induce proinflammatory autoreactive T-cell responses in rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 2010; 69:255-262.
5. Feitsma AL, van der Voort EI, Franken KL etal. Identification of citrullinated vimentin peptides as T cell epitopes in HLA-DR4-positive patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:117-125.
6. James EA, Moustakas AK, Bui J etal. HLA-DR1001 presents 'altered-self' peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010; 62:2909-2918.
7. von Delwig A, Locke J, Robinson JH etal. Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62:143-149.
8. Catalan D, Aravena O, Zuniga R etal. Weak CD4+ T-cell responses to citrullinated vimentin in rheumatoid arthritis patients carrying HLA-DR9 alleles. Rheum Int 2012; 32:1819-1825.
9. Ehrenstein MR, Evans JG, Singh A etal. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004; 200:277-285.
10. Singh JA, Christensen R, Wells GA etal. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; (4):CD007848.
11. Isaacs JD. Therapeutic agents for patients with rheumatoid arthritis and an inadequate response to tumour necrosis factor-alpha antagonists. Exp Opin Biol Ther 2009; 9:1463-1475.
12. Salliot C, Gossec L, Ruyssen-Witrand A etal. Infections during tumour necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. Rheumatology 2007; 46:327-334.
13. Gomez-Reino JJ, Carmona L, Angel Descalzo M. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007; 57:756-761.
14. Carson KR, Evens AM, Richey EA etal. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834-4840.
15. Steinman RM, Nussenzweig MC. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc Natl Acad Sci USA 2002; 99:351-358.
16. Ohnmacht C, Pullner A, King SB etal. Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. J Exp Med 2009; 206:549-559.
17. Collin M, Bigley V, Haniffa M etal. Human dendritic cell deficiency: the missing ID? Nature reviews. Immunology 2011; 11:575-583.
18. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003; 21:685-711.
19. Moser M. Dendritic cells in immunity and tolerance - do they display opposite functions? Immunity 2003; 19:5-8.
20. Jonuleit H, Schmitt E, Schuler G etal. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192:1213-1222.
21. Hawiger D, Inaba K, Dorsett Y etal. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J Exp Med 2001; 194:769-779.
22. Probst HC, Lagnel J, Kollias G etal. Inducible transgenic mice reveal resting dendritic cells as potent inducers of CD8+ T cell tolerance. Immunity 2003; 18:713-720.
23. Diebold SS. Activation of dendritic cells by Toll-like receptors and C-type lectins. Handb Exp Pharmacol 2009; 188:3-30.
24. Kalinski P, Hilkens CM, Wierenga EA etal. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999; 20:561-567.
25. Diebold SS. Determination of T-cell fate by dendritic cells. Immunol Cell Biol 2008; 86:389-397.
26. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002; 195:221-231.
27. van der Kleij D, Latz E, Brouwers JF etal. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization. J Biol Chem 2002; 277:48122-48129.
28. de Jong EC, Vieira PL, Kalinski P etal. Corticosteroids inhibit the production of inflammatory mediators in immature monocyte-derived DC and induce the development of tolerogenic DC3. J Leukoc Biol 1999; 66:201-204.
29. Steinbrink K, Graulich E, Kubsch S etal. CD4(+) and CD8(+) anergic T cells induced by interleukin-10-treated human dendritic cells display antigen-specific suppressor activity. Blood 2002; 99:2468-2476.
30. Sato K, Yamashita N, Baba M etal. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 2003; 18:367-379.
31. Lan YY, Wang Z, Raimondi G etal. 'Alternatively activated' dendritic cells preferentially secrete IL-10, expand Foxp3+CD4+ T cells, and induce long-term organ allograft survival in combination with CTLA4-Ig. J Immunol 2006; 177:5868-5877.
32. Josefowicz SZ, Lu LF, Rudensky AY. Regulatory T cells: mechanisms of differentiation and function. Annu Rev Immunol 2012; 30:531-564.
33. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol 2012; 30:733-758.
34. Qureshi OS, Zheng Y, Nakamura K etal. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011; 332:600-603.
35. Gregori S, Goudy KS, Roncarolo MG. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front Immunol 2012; 3:30.
36. Maldonado RA, von Andrian UH. How tolerogenic dendritic cells induce regulatory T cells. Adv Immunol 2010; 108:111-165.
37. Manicassamy S, Pulendran B. Dendritic cell control of tolerogenic responses. Immunol Rev 2011; 241:206-227.
38. Mellor AL, Baban B, Chandler P etal. Cutting edge: induced indoleamine 2, 3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171:1652-1655.
39. Goubier A, Dubois B, Gheit H etal. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008; 29:464-475.
40. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV etal. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 2007; 204:1757-1764.
41. Sun CM, Hall JA, Blank RB etal. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 Treg cells via retinoic acid. J Exp Med 2007; 204:1775-1785.
42. Misra N, Bayry J, Lacroix-Desmazes S etal. Cutting edge: human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172:4676-4680.
43. Kryczek I, Wei S, Zou L etal. Cutting edge: induction of B7-H4 on APCs through IL-10: novel suppressive mode for regulatory T cells. J Immunol 2006; 177:40-44.
44. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Semin Immunol 2011; 23:252-263.
45. Beriou G, Moreau A, Cuturi MC. Tolerogenic dendritic cells: applications for solid organ transplantation. Curr Opin Organ Transplant 2012; 17:42-47.
46. Voigtlander C, Rossner S, Cierpka E etal. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J Immunother 2006; 29:407-415.
47. Lim DS, Kang MS, Jeong JA etal. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur J Immunol 2009; 39:1334-1343.
48. Ludewig B, Ochsenbein AF, Odermatt B etal. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease. J Exp Med 2000; 191:795-804.
49. Stoop JN, Harry RA, von Delwig A etal. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum 2010; 62:3656-3665.
50. Hilkens CM, Isaacs JD, Thomson AW. Development of dendritic cell-based immunotherapy for autoimmunity. Int Rev Immunol 2010; 29:156-183.
51. Matasic R, Dietz AB, Vuk-Pavlovic S. Dexamethasone inhibits dendritic cell maturation by redirecting differentiation of a subset of cells. J Leukoc Biol 1999; 66:909-914.
52. Giannoukakis N, Bonham CA, Qian S etal. Prolongation of cardiac allograft survival using dendritic cells treated with NF-kB decoy oligodeoxyribonucleotides. Mol Ther 2000; 1:430-437.
53. Penna G, Adorini L. 1 Alpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000; 164:2405-2411.
54. Martin E, Capini C, Duggan E etal. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum 2007; 56:2255-2266.
55. Anderson AE, Sayers BL, Haniffa MA etal. Differential regulation of naive and memory CD4+ T cells by alternatively activated dendritic cells. J Leukoc Biol 2008; 84:124-133.
56. Lu L, Gambotto A, Lee WC etal. Adenoviral delivery of CTLA4Ig into myeloid dendritic cells promotes their in vitro tolerogenicity and survival in allogeneic recipients. Gene Ther 1999; 6:554-563.
57. Kim SH, Kim S, Evans CH etal. Effective treatment of established murine collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express IL-4. J Immunol 2001; 166:3499-3505.
58. Morita Y, Yang J, Gupta R etal. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107:1275-1284.
59. Coates PT, Krishnan R, Kireta S etal. Human myeloid dendritic cells transduced with an adenoviral interleukin-10 gene construct inhibit human skin graft rejection in humanized NOD-scid chimeric mice. Gene Ther 2001; 8:1224-1233.
60. Tan PH, Yates JB, Xue SA etal. Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. Blood 2005; 106:2936-2943.
61. Min WP, Gorczynski R, Huang XY etal. Dendritic cells genetically engineered to express Fas ligand induce donor-specific hyporesponsiveness and prolong allograft survival. J Immunol 2000; 164:161-167.
62. Kim SH, Kim S, Oligino TJ etal. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol Ther 2002; 6:584-590.
63. Liu Z, Xu X, Hsu HC etal. CII-DC-AdTRAIL cell gene therapy inhibits infiltration of CII-reactive T cells and CII-induced arthritis. J Clin Invest 2003; 112:1332-1341.
64. Liang X, Lu L, Chen Z etal. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival. Transplantation 2003; 76:721-729.
65. Xu H, Chen T, Wang HQ etal. Prolongation of rat intestinal allograft survival by administration of donor interleukin-12 p35-silenced bone marrow-derived dendritic cells. Transplant Proc 2006; 38:1561-1563.
66. Li R, Zheng X, Popov I etal. Gene silencing of IL-12 in dendritic cells inhibits autoimmune arthritis. J Transl Med 2012; 10:19.
67. Steinbrink K, Wolfl M, Jonuleit H etal. Induction of tolerance by IL-10-treated dendritic cells. J Immunol 1997; 159:4772-4780.
68. Yarilin D, Duan R, Huang YM etal. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin Exp Immunol 2002; 127:214-219.
69. Boks MA, Kager-Groenland JR, Haasjes MS etal. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction - a comparative study of human clinical-applicable DC. Clin Immunol 2012; 142:332-342.
70. Turnquist HR, Raimondi G, Zahorchak AF etal. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J Immunol 2007; 178:7018-7031.
71. Salazar L, Aravena O, Abello P etal. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann Rheum Dis 2008; 67:1235-1241.
72. Zheng J, Jiang HY, Li J etal. MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-kappaB signalling pathways. Allergy 2012; 67:362-370.
73. Valencia J, Hernandez-Lopez C, Martinez VG etal. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J Immunol 2011; 187:4129-4139.
74. Stoop JN, Robinson JH, Hilkens CM. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann Rheum Dis 2011; 70:1526-1533.
75. Bianco NR, Kim SH, Ruffner MA etal. Therapeutic effect of exosomes from indoleamine 2, 3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum 2009; 60:380-389.
76. Giannoukakis N, Phillips B, Finegold D etal. Phase I (safety) study of autologous tolerogenic dendritic cells in type 1 diabetic patients. Diabetes Care 2011; 34:2026-2032.
77. Thomas R, Street S, Ramnoruth N etal. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerising dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70 (Suppl 3):169.
78. Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M etal. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol 2012; 42:771-782.
79. Machen J, Harnaha J, Lakomy R etal. Antisense oligonucleotides down-regulating costimulation confer diabetes-preventive properties to nonobese diabetic mouse dendritic cells. J Immunol 2004; 173:4331-4341.
80. Martin E, O'Sullivan B, Low P etal. Antigen-specific suppression of a primed immune response by dendritic cells mediated by regulatory T cells secreting interleukin-10. Immunity 2003; 18:155-167.
81. Thompson AG, O'Sullivan BJ, Beamish H etal. T cells signaled by NF-kappa B-dendritic cells are sensitized not anergic to subsequent activation. J Immunol 2004; 173:1671-1680.
82. Anderson AE, Swan DJ, Sayers BL etal. LPS activation is required for migratory activity and antigen presentation by tolerogenic dendritic cells. J Leukoc Biol 2009; 85:243-250.
83. Harry RA, Anderson AE, Isaacs JD etal. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann Rheum Dis 2010; 69:2042-2050.
84. Inaba K, Turley S, Iyoda T etal. The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J Exp Med 2000; 191:927-936.
85. Garrod KR, Chang CK, Liu FC etal. Targeted lymphoid homing of dendritic cells is required for prolongation of allograft survival. J Immunol 2006; 177:863-868.
86. Bai Y, Liu J, Wang Y etal. L-selectin-dependent lymphoid occupancy is required to induce alloantigen-specific tolerance. J Immunol 2002; 168:1579-1589.
87. Ochando JC, Yopp AC, Yang Y etal. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005; 174:6993-7005.
88. Cush JJ, Pietschmann P, Oppenheimer-Marks N etal. The intrinsic migratory capacity of memory T cells contributes to their accumulation in rheumatoid synovium. Arthritis Rheum 1992; 35:1434-1444.
89. Thomas R, Davis LS, Lipsky PE. Rheumatoid synovium is enriched in mature antigen-presenting dendritic cells. J Immunol 1994; 152:2613-2623.
90. Yamana J, Yamamura M, Okamoto A etal. Resistance to IL-10 inhibition of interferon gamma production and expression of suppressor of cytokine signaling 1 in CD4+ T cells from patients with rheumatoid arthritis. Arthritis Res Ther 2004; 6:R567-577.
91. Zhu L, Ji F, Wang Y etal. Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol 2006; 177:8226-8233.
92. Cluff CW. Monophosphoryl lipid A (MPL) as an adjuvant for anti-cancer vaccines: clinical results. Adv Exp Med Biol 2009; 667:111-123.
93. Radstake TR, van Lent PL, Pesman GJ etal. High production of proinflammatory and Th1 cytokines by dendritic cells from patients with rheumatoid arthritis, and down regulation upon FcgammaR triggering. Ann Rheum Dis 2004; 63:696-702.
94. Baldwin HM, Ito-Ihara T, Isaacs JD etal. Tumour necrosis factor alpha blockade impairs dendritic cell survival and function in rheumatoid arthritis. Ann Rheum Dis 2010; 69:1200-1207.
95. Tsark EC, Wang W, Teng YC etal. Differential MHC class II-mediated presentation of rheumatoid arthritis autoantigens by human dendritic cells and macrophages. J Immunol 2002; 169:6625-6633.
96. Seward RJ, Drouin EE, Steere AC etal. Peptides presented by HLA-DR molecules in synovia of patients with rheumatoid arthritis or antibiotic-refractory Lyme arthritis. Mol Cell Proteomics 2011; 10:M110-002477.
97. van Beers JJ, Schwarte CM, Stammen-Vogelzangs J etal. The RA synovial fluid citrullinome reveals novel citrullinated epitopes in apolipoprotein E, myeloid nuclear differentiation antigen and beta-actin. Arthritis Rheum 2013; 65:69-80.
98. Canavan JB, Afzali B, Scotta C etal. A rapid diagnostic test for human regulatory T-cell function to enable regulatory T-cell therapy. Blood 2012; 119:e57-66.
99. Bohne F, Martinez-Llordella M, Lozano JJ etal. Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. J Clin Invest 2012; 122:368-382.
100. Nielen MM, van Schaardenburg D, Reesink HW etal. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004; 50:380-386.
101. Isaacs JD. The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 2010; 10:605-611.
102. Morgan AW, Hale G, Rebello PR etal. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. Q J Med 2008; 101:299-306.